R
Ragini R. Kudchadkar
Researcher at Emory University
Publications - 139
Citations - 8650
Ragini R. Kudchadkar is an academic researcher from Emory University. The author has contributed to research in topics: Melanoma & Ipilimumab. The author has an hindex of 36, co-authored 129 publications receiving 6414 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber,Mario Mandalà,Michele Del Vecchio,Helen Gogas,Ana Arance,C. Lance Cowey,Stéphane Dalle,Michael Schenker,Vanna Chiarion-Sileni,Ivan Marquez-Rodas,Jean-Jacques Grob,Marcus O. Butler,Mark R. Middleton,Michele Maio,Victoria Atkinson,Paola Queirolo,Rene Gonzalez,Ragini R. Kudchadkar,Michael Smylie,Nicolas Meyer,Laurent Mortier,Michael B. Atkins,Georgina V. Long,Shailender Bhatia,Céleste Lebbé,Piotr Rutkowski,Kenji Yokota,Naoya Yamazaki,Tae M. Kim,Veerle de Pril,J Sabater,Anila Qureshi,James Larkin,Paolo A. Ascierto +33 more
TL;DR: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence‐free survival and a lower rate of grade 3 or 4 adverse events than adjuant therapy with ipilimumab.
Journal ArticleDOI
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,Ragini R. Kudchadkar,Natalie J. Miller,Lakshmanan Annamalai,Sneha Berry,Elliot Chartash,Adil Daud,Steven P. Fling,Philip Friedlander,Harriet M. Kluger,Holbrook E Kohrt,Lisa Lundgren,Kim Margolin,Alan Mitchell,Thomas Olencki,Drew M. Pardoll,Sunil Reddy,E. Shantha,William H. Sharfman,Elad Sharon,Lynn Shemanski,Michi M. Shinohara,Joel C. Sunshine,Janis M. Taube,John A. Thompson,John A. Thompson,Steven M. Townson,Jennifer H. Yearley,Suzanne L. Topalian,Martin A. Cheever,Martin A. Cheever +32 more
TL;DR: First-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56% and effectiveness was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing.
Journal ArticleDOI
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein Abdul-Hassan Tawbi,Peter A. Forsyth,Alain Algazi,Omid Hamid,F. Stephen Hodi,Stergios J. Moschos,Nikhil I. Khushalani,Karl D. Lewis,Christopher D. Lao,Michael A. Postow,Michael B. Atkins,Marc S. Ernstoff,David A. Reardon,Igor Puzanov,Ragini R. Kudchadkar,Reena Thomas,Ahmad A. Tarhini,Ahmad A. Tarhini,Anna C. Pavlick,Joel Jiang,Alexandre Avila,Sheena Demelo,Kim Margolin +22 more
TL;DR: Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases.
Journal ArticleDOI
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial
Richard D. Carvajal,Jeffrey A. Sosman,Jorge F. Quevedo,Mohammed M. Milhem,Anthony M. Joshua,Ragini R. Kudchadkar,Gerald P. Linette,Thomas F. Gajewski,Jose Lutzky,David H. Lawson,Christopher D. Lao,Patrick J. Flynn,Mark R. Albertini,Takami Sato,Karl D. Lewis,Austin Doyle,Kristin K. Ancell,Katherine S. Panageas,Mark J. Bluth,Cyrus V. Hedvat,Joseph P. Erinjeri,Grazia Ambrosini,Brian P. Marr,David H. Abramson,David H. Abramson,Mark A. Dickson,Mark A. Dickson,Jedd D. Wolchok,Jedd D. Wolchok,Paul B. Chapman,Paul B. Chapman,Gary K. Schwartz,Gary K. Schwartz +32 more
TL;DR: In this hypothesis-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy resulted in a modestly improved progression-free survival and response rate; however, no improvement in overall survival was observed.
Journal ArticleDOI
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden,Alexander Guminski,Ralf Gutzmer,Luc Dirix,Karl D. Lewis,Patrick Combemale,R. Herd,Ragini R. Kudchadkar,Uwe Trefzer,Sven Gogov,Celine Pallaud,Tingting Yi,Manisha Mone,Martin Kaatz,Carmen Loquai,Alexander J. Stratigos,Hans Joachim Schulze,Ruth Plummer,Anne Lynn S. Chang,Frank Cornelis,John T. Lear,Dalila Sellami,Reinhard Dummer +22 more
TL;DR: The benefit-to-risk profile of 200 mg sonidegib might offer a new treatment option for patients with advanced basal cell carcinoma, a population that is difficult to treat.